RPRX
Royalty Pharma Plc
NASDAQ: RPRX · HEALTHCARE · BIOTECHNOLOGY
$49.49
-0.10% today
Updated 2026-04-29
Market cap
$29.37B
P/E ratio
27.83
P/S ratio
12.35x
EPS (TTM)
$1.78
Dividend yield
1.77%
52W range
$31 – $50
Volume
3.2M
Royalty Pharma Plc (RPRX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+11.3%
Last 4 quarters
Revenue YoY growth
+4.8%
Most recent quarter
EPS YoY growth
+320.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+2.2%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+7.8%
2025-11-05
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-11 | $1.47 | +10.5% | $44.21 | $44.80 | +1.3% |
| 2025-11-05 | $1.17 | +12.5% | $37.84 | $40.78 | +7.8% |
| 2025-08-06 | $1.14 | +10.7% | $37.91 | $37.01 | -2.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $1.33 | $1.47 | +10.5% | $621.99M | +4.8% |
| 2025-09-30 | $1.04 | $1.17 | +12.5% | $609.29M | +7.9% |
| 2025-06-30 | $1.03 | $1.14 | +10.7% | $578.66M | +7.7% |
| 2025-03-31 | $0.95 | $1.06 | +11.6% | $568.25M | +0.0% |
| 2024-12-31 | $0.25 | $0.35 | +40.0% | $593.64M | -0.4% |
| 2024-09-30 | $0.93 | $0.92 | -1.1% | $564.69M | +5.3% |
| 2024-06-30 | $0.97 | $0.96 | -1.0% | $537.27M | -0.2% |
| 2024-03-31 | $0.98 | $0.98 | +0.0% | $567.98M | — |
| 2023-12-31 | $1.00 | $1.52 | +52.0% | $596.07M | — |
| 2023-09-30 | $0.77 | $0.79 | +2.6% | $536.31M | — |
| 2023-06-30 | $0.81 | $0.84 | +3.7% | $538.20M | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $5.17 | $2.5B | +5.5% | 4 | high |
| 2028 (E) | $5.95 | $2.8B | +6.4% | 4 | medium |
| 2029 (E) | $6.42 | $3.0B | +7.1% | 4 | medium |
Frequently asked questions
Has Royalty Pharma Plc beaten earnings estimates?
Royalty Pharma Plc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +11.3% over the last 4 quarters.
How does RPRX stock react to earnings?
RPRX stock has moved an average of +2.2% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Royalty Pharma Plc's revenue growth rate?
Royalty Pharma Plc reported year-over-year revenue growth of +4.8% in its most recent quarter, with EPS growing +320.0% year-over-year.
What is the expected EPS for RPRX in 2026?
Analysts expect Royalty Pharma Plc to report EPS of $5.17 for fiscal year 2026, on revenue of $2.5B, based on estimates from 4 analysts.